© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 16, 1221-1226,
August 21, 2002
© 2002 Oxford University Press
ARTICLE |
On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance
Correspondence to: Colin B. Begg, Ph.D., Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021 (e-mail: beggc{at}mskcc.org).
Background: Estimating the lifetime risk associated with (i.e., the penetrance of) genetic abnormalities that predispose individuals to cancer is important for genetic counseling. (Penetrance may be estimated from the degree of familial aggregation of cancer, that is, the extent to which cancers cluster in families.) Early penetrance studies of BRCA1 and BRCA2 mutations used high-risk families with multiple cases of breast cancer, a study design that led to very high penetrance estimates. However, such studies were subject to potential ascertainment biases. To offset such biases, recent studies have used data from family members of probands ascertained from population-based incident cases of cancer. The use of case probands is, however, also subject to bias because all risk factors are over-represented in case patients. To draw attention to this problem, literature on the penetrance of breast cancer in BRCA1 and BRCA2 carriers is reviewed. Methods: A theory is presented to show that the use of case probands is itself biased, leading to inflated penetrance estimates. The strategy is unbiased only if all carriers share an identical risk. Any unexplained heterogeneity of risk caused by unknown genetic or shared environmental factors within families leads to an inflated estimate of penetrance. Results: Eight published studies using population-based methods are reviewed. All but one of the family-based studies used case probands. Conclusions: Penetrance estimates from case proband studies must be inflated if other factors influence breast cancer risk in addition to the specific genetic abnormality. Thus, women with such genetic abnormalities and a strong family history of breast cancer are likely to possess a much higher risk for breast cancer than women with such abnormalities but without a strong family history. Methodologic techniques to improve the prediction of cancer risk are needed.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. J. Rosanoff and R. Ottman Penetrance of LGI1 mutations in autosomal dominant partial epilepsy with auditory features Neurology, August 19, 2008; 71(8): 567 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Weiss Tilting at Quixotic Trait Loci (QTL): An Evolutionary Perspective on Genetic Causation Genetics, August 1, 2008; 179(4): 1741 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, L. N. Clark, E. D. Louis, H. Mejia-Santana, J. Harris, L. J. Cote, C. Waters, H. Andrews, B. Ford, S. Frucht, et al. Risk of Parkinson Disease in Carriers of Parkin Mutations: Estimation Using the Kin-Cohort Method Arch Neurol, April 1, 2008; 65(4): 467 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Offit and J. E. Garber Time to Check CHEK2 in Families With Breast Cancer? J. Clin. Oncol., February 1, 2008; 26(4): 519 - 520. [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Begg, R. W. Haile, A. Borg, K. E. Malone, P. Concannon, D. C. Thomas, B. Langholz, L. Bernstein, J. H. Olsen, C. F. Lynch, et al. Variation of Breast Cancer Risk Among BRCA1/2 Carriers JAMA, January 9, 2008; 299(2): 194 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kadouri, A. Hubert, Y. Rotenberg, T. Hamburger, M. Sagi, C. Nechushtan, D. Abeliovich, and T. Peretz Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations J. Med. Genet., July 1, 2007; 44(7): 467 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, L. N. Clark, K. Marder, and D. Rabinowitz Nonparametric estimation of age-at-onset distributions from censored kin-cohort data Biometrika, June 1, 2007; 94(2): 403 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chen and G. Parmigiani Meta-Analysis of BRCA1 and BRCA2 Penetrance J. Clin. Oncol., April 10, 2007; 25(11): 1329 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Smith, A Moran, M C Boyd, M Bulman, A Shenton, L Smith, R Iddenden, E R Woodward, F Lalloo, E R Maher, et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening J. Med. Genet., January 1, 2007; 44(1): 10 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Offit BRCA Mutation Frequency and Penetrance: New Data, Old Debate J Natl Cancer Inst, December 6, 2006; 98(23): 1675 - 1677. [Full Text] [PDF]
|
|
|
|
|
|
H. A. Risch, J. R. McLaughlin, D. E. C. Cole, B. Rosen, L. Bradley, I. Fan, J. Tang, S. Li, S. Zhang, P. A. Shaw, et al. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin-Cohort Study in Ontario, Canada J Natl Cancer Inst, December 6, 2006; 98(23): 1694 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. N. Clark, Y. Wang, E. Karlins, L. Saito, H. Mejia-Santana, J. Harris, E. D. Louis, L. J. Cote, H. Andrews, S. Fahn, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease Neurology, November 28, 2006; 67(10): 1786 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berwick, I. Orlow, A. J. Hummer, B. K. Armstrong, A. Kricker, L. D. Marrett, R. C. Millikan, S. B. Gruber, H. Anton-Culver, R. Zanetti, et al. The Prevalence of CDKN2A Germ-Line Mutations and Relative Risk for Cutaneous Malignant Melanoma: An International Population-Based Study. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1520 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Antoniou, P. D.P. Pharoah, D. F. Easton, and D. G. Evans BRCA1 and BRCA2 Cancer Risks J. Clin. Oncol., July 10, 2006; 24(20): 3312 - 3313. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hinney, T. Bettecken, P. Tarnow, H. Brumm, K. Reichwald, P. Lichtner, A. Scherag, T. T. Nguyen, P. Schlumberger, W. Rief, et al. Prevalence, Spectrum, and Functional Characterization of Melanocortin-4 Receptor Gene Mutations in a Representative Population-Based Sample and Obese Adults from Germany J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1761 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Andrieu, D. E. Goldgar, D. F. Easton, M. Rookus, R. Brohet, A. C. Antoniou, S. Peock, G. Evans, D. Eccles, F. Douglas, et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst, April 19, 2006; 98(8): 535 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tryggvadottir, H. Sigvaldason, G. H. Olafsdottir, J. G. Jonasson, T. Jonsson, H. Tulinius, and J. E. Eyfjord Population-Based Study of Changing Breast Cancer Risk in Icelandic BRCA2 Mutation Carriers, 1920-2000 J Natl Cancer Inst, January 18, 2006; 98(2): 116 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Goldstein and M. A. Tucker A Piece of the Melanoma Puzzle J Natl Cancer Inst, October 19, 2005; 97(20): 1486 - 1487. [Full Text] [PDF]
|
|
|
|
|
|
C. B. Begg, I. Orlow, A. J. Hummer, B. K. Armstrong, A. Kricker, L. D. Marrett, R. C. Millikan, S. B. Gruber, H. Anton-Culver, R. Zanetti, et al. Lifetime Risk of Melanoma in CDKN2A Mutation Carriers in a Population-Based Sample J Natl Cancer Inst, October 19, 2005; 97(20): 1507 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. D. Nelson, L. H. Huffman, R. Fu, and E. L. Harris Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force Ann Intern Med, September 6, 2005; 143(5): 362 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C J van Asperen, R M Brohet, E J Meijers-Heijboer, N Hoogerbrugge, S Verhoef, H F A Vasen, M G E M Ausems, F H Menko, E B Gomez Garcia, J G M Klijn, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary J. Med. Genet., September 1, 2005; 42(9): 711 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Bracken Genomic Epidemiology of Complex Disease: The Need for an Electronic Evidence-based Approach to Research Synthesis Am. J. Epidemiol., August 15, 2005; 162(4): 297 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Quehenberger, H F A Vasen, and H C van Houwelingen Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment J. Med. Genet., June 1, 2005; 42(6): 491 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Narod and K. Offit Prevention and Management of Hereditary Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1656 - 1663. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Garber and K. Offit Hereditary Cancer Predisposition Syndromes J. Clin. Oncol., January 10, 2005; 23(2): 276 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Agnantis, E. Paraskevaidis, and D. Roukos Editorial: Preventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance Ann. Surg. Oncol., December 1, 2004; 11(12): 1030 - 1034. [Full Text] [PDF]
|
|
|
|
|
|
A Dempfle, A Hinney, M Heinzel-Gutenbrunner, M Raab, F Geller, T Gudermann, H Schafer, and J Hebebrand Large quantitative effect of melanocortin-4 receptor gene mutations on body mass index J. Med. Genet., October 1, 2004; 41(10): 795 - 800. [Full Text] [PDF]
|
|
|
|
|
|
V. Chaudru, A. Chompret, B. Bressac-de Paillerets, A. Spatz, M.-F. Avril, and F. Demenais Influence of Genes, Nevi, and Sun Sensitivity on Melanoma Risk in a Family Sample Unselected by Family History and in Melanoma-Prone Families J Natl Cancer Inst, May 19, 2004; 96(10): 785 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ottman, M. R. Winawer, S. Kalachikov, C. Barker-Cummings, T. C. Gilliam, T. A. Pedley, and W. A. Hauser LGI1 mutations in autosomal dominant partial epilepsy with auditory features Neurology, April 13, 2004; 62(7): 1120 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hirsch, A. Shimamura, L. Moreau, S. Baldinger, M. Hag-alshiekh, B. Bostrom, S. Sencer, and A. D. D'Andrea Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood Blood, April 1, 2004; 103(7): 2554 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Thull and V. G. Vogel Recognition and Management of Hereditary Breast Cancer Syndromes Oncologist, February 1, 2004; 9(1): 13 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Garber and S. Syngal One Less Thing to Worry About: The Shrinking Spectrum of Tumors in BRCA Founder Mutation Carriers J Natl Cancer Inst, January 7, 2004; 96(1): 2 - 3. [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. King, J. H. Marks, and J. B. Mandell Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 Science, October 24, 2003; 302(5645): 643 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Risch and S. A. Narod Re: Cancer Risks in BRCA1 Carriers: Time for the Next Generation of Studies J Natl Cancer Inst, May 21, 2003; 95(10): 758 - 758. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Smith, D. Saslow, K. Andrews Sawyer, W. Burke, M. E. Costanza, W. P. Evans III, R. S. Foster Jr., E. Hendrick, H. J. Eyre, and S. Sener American Cancer Society Guidelines for Breast Cancer Screening: Update 2003 CA Cancer J Clin, May 1, 2003; 53(3): 141 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Amos Re: On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance J Natl Cancer Inst, January 1, 2003; 95(1): 74 - 75. [Full Text] [PDF]
|
|
|
|
|
|
P. D. P. Pharoah, A. Antoniou, J. Hopper, and D. Easton Re: On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance J Natl Cancer Inst, January 1, 2003; 95(1): 75 - 76. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Whittemore and G. Gong Re: On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance J Natl Cancer Inst, January 1, 2003; 95(1): 76 - 77. [Full Text] [PDF]
|
|
|
|
|
|
W. Burke and M. Austin RESPONSE: Re: On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance J Natl Cancer Inst, January 1, 2003; 95(1): 78 - 79. [Full Text] [PDF]
|
|
|
|
|
|
H. A. Risch and S. A. Narod Re: On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance J Natl Cancer Inst, January 1, 2003; 95(1): 73 - 74. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Satagopan, J. Boyd, N. D. Kauff, M. Robson, L. Scheuer, S. Narod, and K. Offit Ovarian Cancer Risk in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations Clin. Cancer Res., December 1, 2002; 8(12): 3776 - 3781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Minerva BMJ, August 31, 2002; 325(7362): 502 - 502. [Full Text] [PDF]
|
|
|
|
|
|
W. Burke and M. A. Austin Genetic Risk in Context: Calculating the Penetrance of BRCA1 and BRCA2 Mutations J Natl Cancer Inst, August 21, 2002; 94(16): 1185 - 1187. [Full Text] [PDF]
|
|